Drug Delivery in Oncology: From Basic Research to Cancer Therapy 3 Volume Set

In this first authoritative overview on modern cancer chemotherapy 100 international specialists have contributed their experience and recent data for what is likely to become the gold standard in the field.
The authors summarize knowledge gained over the past decade, from basic concepts to successful applications in the clinic, covering active and passive targeting strategies as well as tissue–specific approaches. All current and future targeted delivery systems are discussed, from ligand–based to antibody–based polymer–based systems, right up to micro– and nanoparticulate systems. A special section covers the delivery of nucleic acid therapeutics, such as siRNA, miRNA and antisense nucleotides. In each case, a description of the basic technique is followed by a discussion of the latest preclinical and clinical developments in the field.
By virtue of its clear and didactic structure, rich illustrative material and summary chapters, this handbook and ready reference enables the efficient transfer of knowledge between different disciplines, from basic research to the clinician and vice versa. It is equally well suited for professionals, researchers and students in medical oncology and cancer biology, and is also excellent for teaching medical students the foundations of 21st century cancer chemotherapy.


Spis treści:
PRINCIPLES OF TUMOR TARGETING
Limits of Conventional Cancer Chemotherapy
Pathophysiological and Vascular Characteristics of Tumors in Relation to Drug Delivery
The EPR–Effect in Relation to Tumor Targeting
Pharmacokinetics of Antibodies and Albumin: Implications for the Role of the MHC Receptor FcRn and T Cell Receptor for the Design of Drug Delivery Systems
Development of Cancer Targeting Ligands and Ligand–Drug Conjugates
Two–Step Approaches to Cancer Therapy
TUMOR IMAGING
Imaging Techniques in Drug Development and Clinical Practice
Magnetic Nanop articles in MR Imaging and Drug Delivery
Near Infrared Imaging
Imaging Techniques for Cancer –
From Microscopy to Quantum Dots and Nanoshells
Preclinical and Clinical Tumor Imaging with PET and SPECT/CT
MACROMOLECULAR DRUG DELIVERY SYSTEMS
Antibody–Based Systems
Empowered Antibodies for Cancer Therapy
Vascular Targeting to Penetrate Solid Tumors
Considerations of Linker Technologies
Clinical Experience with Maytansine Antibody Conjugates
Mylotarg and Beyond
Antibodies for the Delivery of Radionuclides
Bispecific Antibodies and Immune Therapy Targeting
POLYMER–BASED SYSTEMS
Design of Polymer–Drug Conjugates
Dendritic Polymers as Drug Delivery Systems in Oncology
Self–Immolative Systems
Ligand–Assisted Targeting of Polymer Therapeutics
Drug Conjugates with Poly(ethylene)glycole
Thermally Responsive Polymers
Polysaccharide–Based Drug Conjugates for Tumor Targeting
Serum Proteins as Drug Carriers of Anticancer Agents
Combination Therapy with Drug Polymer Conjugates
Clinical Experience with Drug Polymer Conjugates
NANO– AND MICROPARTICULATE DRUG DELIVERY SYSTEMS
Nanocarriers as Delivery Systems
The Development of Pegylated Liposomes
Immunoliposomes
Responsive Liposomes (for Solid Tumor Therapy)
Liposomal Formulations for Optimized Combination Therapy
POLYMER–BASED SYSTEMS
Micellar Strcutures as Drug Delivery Systems
Tailor–Made Hydrogels for Tumor Delivery
pH–Triggered Micelles
Albumin Nanoparticles
Carbon Nanotubes
LIGAND–BASED DRUG DELIVERY SYSTEMS
Cell–Penetrating Peptides in Cancer Targeting
Subcellular Targeting
Targeting to Peptide Receptors
Aptamer Conjugates
Design and Synthesis of Drug Conjugates of Vitamins and Growth Factors
Drug Conjugates with Fatty Acids
SPECIAL TOPICS
RNA Drug Delivery Approaches
Local Gene Delivery for Therapy of Solid Tumors
RNA Delivery Using Viral Vectors
Design of Targeted Protein Toxins
CNS Drug Delivery
Liver Tumor Targeting
Drug Delivery in Photodynamic Therapy
Tumor Targeting Strategies with Anticancer Platinum Complexes


Nota biograficzna:
Felix Kratz graduated in Chemistry from the University of Heidelberg (Germany) in 1991. He then carried out postdoctoral research at the Bioinorganic Institute of the University of Florence (Italy). Since 1994 he has been Head of Macromolecular Prodrugs at the Tumor Biology Center in Freiburg (Germany) where he is in charge of organizing and managing translational research from the laboratory to the clinic.
Peter Senter holds a Ph.D. in Chemistry from the University of Illinois, and an A.B. in Biochemistry from the University of California, Berkeley. He currently leads the chemistry department at Seattle Genetics, having previously worked for Cytokine Networks, Inc., the Bristol–Myers Squibb Pharmaceutical Research Institute and the Dana–Farber Cancer Institute. Dr. Senter is also an Affiliate Professor of Bioengineering at the University of Washington.
Henning Steinhagen graduated in Organic Chemistry from the University of Heidelberg (Germany) in 1998. He then joined the group of Prof. E.J. Corey at Harvard University, Cambridge (USA) as postdoctoral fellow. He continued his career to work in medicinal chemistry research at Bayer in Wuppertal and as senior scientist at Aventis in Frankfurt (Germany), where he was promoted to Director. Since 2009 he is the head of Global Drug Discovery at Grunenthal in Aachen (Germany).